Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.

Kanchi PatellMatthew KurianJorge A GarciaPrateek MendirattaPedro C BarataAngela JiaDaniel E SprattJason R Brown

Published in: Expert review of anticancer therapy (2023)

Lu-PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.

Keyphrases

prostate cancer
end stage renal disease
chronic kidney disease
phase iii
small cell lung cancer
ejection fraction
squamous cell carcinoma
computed tomography
pet imaging
patient reported outcomes
double blind
patient reported